#1BEAUTYHEALTH™ Analyst & Investor Day September 15, 2022#2The road to BeautyHealth Brent Saunders Executive Chairman BEAUTYHEALTH#3What makes Hydrafacial attractive? 3 Criteria Leading position in attractive and growing industry Scientific / brand differentiation Sustainable competitive advantages Suitable platform to build a leading aesthetics technology company focused on allied healthcare professionals Long-term growth prospects and drivers Cash pay / no reimbursement risk Global commercial infrastructure Profitable hydrafacial BEAUTYHEALTH™#4An accomplished executive committee 4 Andrew Stanleick President & Chief Executive Officer Stefanie Gebauer President, Southeast Asia Liyuan Woo Chief Financial Officer Mingo Ku President, North Asia Jwala Karnik, MD EVP of Global Strategy & Partnerships Dan Watson EVP, Sales Americas Ben Baum Chief Experience Officer Amy Juaristi Head of Corporate Affairs Jon Arnold President, EMEA Kellie Sears Chief Human Resources Officer Paul Bokota Vice President & General Counsel BEAUTYHEALTH™#5BEAUTYHEALTH™ Analyst & Investor Day September 15, 2022#6The future of BeautyHealth Andrew Stanleick President & Chief Executive Officer BEAUTYHEALTH#7Welcome BOONG BEAUTYHEALTH#8Today's objectives 8 1 2 3 Present 5-Point Master Plan and new business insights Review 3-Year Strategic Growth Plan with significant growth and EBITDA potential Introduce the BeautyHealth Executive Committee BEAUTYHEALTH#9Today's agenda The road to BeautyHealth Brent Saunders Executive Chairman Q&A The future of Beauty Health Andrew Stanleick President & Chief Executive Officer Closing remarks Ben Baum Chief Experience Officer Delivering the three-year plan Building brand love Andrew Stanleick Liyuan Woo President & Chief Executive Officer Chief Financial Officer Clinical approach behind the Hydrafacial glow Jwala Karnik, MD EVP of Global Strategy & Partnerships Fireside chat: power of an omni-channel strategy Jwala Karnik, MD Mingo Ku EVP of Global President, Strategy & Partnerships North Asia Dan Watson EVP, Sales Americas Break BEAUTYHEALTH™#10Today's three takeaways 10 q 1. CATEGORY CREATOR with a differentiated product offering, business model and community 1800 2. PROFITABLE GROWTH across geographies and categories in a huge and growing TAM 20 3. INNOVATIVE TECHNOLOGY and a powerful flywheel drives our growth BEAUTYHEALTH™#11Who is BeautyHealth? BEAUTYHEALTH™#12Aesthetics Beauty Health Wellness#13Spa Medical At-home Retail#14Experiences Results Community Product#15BEAUTYHEALTH™#16We are a purpose driven company We believe Everyone deserves to feel good about themselves. We work with purpose We don't just make great products, we build confidence. Our vision Become the world's leading beauty health and wellness platform, fueled by a community of engaged providers, aestheticians and consumers. 16 BEAUTYHEALTH™#17We are a global leader in beauty health Our financials Strong balance sheet to fuel growth $340 - 350mm 2022E net sales 17 $50mm 2022E Adjusted EBITDA $821mm Cash & equiv. at June 30, 2022 Medical ADVANCED DERMATOLOGY and Cosmetic Surgery Available at omni-channel partners NASSIFMD Our community Partners you know, wherever you live, work, and play OVME hydrafacial keravive. Non-Medical Marriott Our brands FOUR SEASONS EQUINOX Retail SEPHORA ULTA BEAUTY Galeries Lafayette JOHN LEWIS & PARTNERS Innovating with fellow skin experts JLO BEAUTY™ Murad. ZO SKIN HEALTH Note: Adjusted EBITDA is a non-GAAP measure; please refer to the appendix for a discussion of the definition of this measure and important information regarding the assumptions underlying the outlook; data as of June 30, 2022. Our global footprint Loved around the world 90+ Countries -23,000 Delivery systems 35,000+ Aestheticians educated BEAUTYHEALTH™#18We deliver diversified net sales regionally % net sales, FY 2021 18 Americas 65% EMEA 18% APAC 17% BEAUTYHEALTH™#19We are playing in a large, high-growth market 19 Hospitality 143,000¹ By Channel 500,000+ Total Doors² Spa 129,000¹ Medical 172,500¹ Hair $100bn 3% growth³ By Category $250bn+ Total Skin and Hair Source: McKinsey & Company feasibility analysis (2022), management estimates, Statista; 1. Excludes estimates for distributor markets; 2. Includes estimates for distributor markets; 3. 2022E-2025E CAGRS. Skin $150bn 5% growth³ BEAUTYHEALTH™#2020 Macro tailwinds are with us, and consumer demand is all-weather Tailwinds Societal shift toward health and wellness Broader definition of beauty: embrace your version of beauty, whatever that may be Reduced stigma, increased access, and advances in aesthetic procedures Post-pandemic Zoom boom: our face is our business card Headwinds Geopolitical uncertainty Macroeconomic environment COVID-19 lockdowns Supply chain disruptions CCCC SEPHORA CCOO COCO PC C C C C C BEAUTYHEALTH™#21We serve an upper middle class and resilient consumer 21 U.S. consumer archetype $94K Annual household income 30s Average age >20% Male 33% LatinX High income less susceptible to economic downturns Source: Company data; Grand View Research, Hair Restoration Market Share Analysis Report, 2021-2028; media reports. Young with high LTV potential Over-indexed with demographic leading beauty spend Highly desirable consumer that craves beauty and health Global men's grooming market expected to reach $81.2bn by 2024 BEAUTYHEALTH™#22Our provider community is booming Skincare specialist jobs are expected to grow +29% by 2030¹ outpacing job growth in other categories ution 22 1. Bureau of Labor Statistics, U.S. Department of Labor, Occupational Outlook Handbook, Skincare Specialists, at https://www.bls.gov/ooh/personal-care-and-service/skincare- specialists.htm (visited September 2022). #GLOW VO drafaçal Cultivated aesthetician community that provides edge to capture growth BEAUTYHEALTH™#23Today, Hydrafacial is a love brand with a legion of provider and consumer fans I GOT THAT HYDRAFACIAL #GLOW drafacial 23 hydrafac ydr I GOT THAT Indra EXPERIENCE THE ALO GLOW hydrafacial Source: Company data as of 2022. hydrafacial IF YOU KNO YOU GLOW 44 NPS Fol hydrafacial hydrafacial bydrada Lythich Sew Sk of Al CALM LEADER HEALTHCARE FACIAL BAR Tams SMOOTH& hyd 3 THE HYDRATE PS 30 MINUTES IN OF YOUR on technok SETURZ hydrafacial 1 BEAUTYHEALTH™#24Beauty Health may be new to the public markets, but we have led technological innovation for years 24 Esta in LITI UNIT NO CALIBRATION REQUIRED 2007 1997 S.A.F.E Smoke Evacuation Hyd2011 Core Edge Systems ** Delphia 2000- Delphia Micro-Dermabrasion ACTIVA BETO HO CEN ANFION hydrafacial 2012 Allegro ARE FIRE 2005 The Tower 2016 Elite O OFF WAY 0.OFF 2008 The Wave Perk 2017 Perk 1:09 DOFF kobe Wave SYSTEM RINSE Indralacal E 2009 Facial Nectro Nectre 0 0 BENZ ETYCE SYSTEM 0 2022 Syndeo BEAUTYHEALTH™#25It's not a facial. It's a Hydrafacial. Treats the skin more deeply and fully Extract Remove debris from pores with painless suction Cleanse Gentle exfoliation and relaxing resurfacing to uncover a new layer of skin Hydrate Saturate surface with antioxidants and peptides to create instantly gratifying glow (D 25 B With the touch of our magic wand → Patented vortex fusion wand → Enhances any skincare formula with a more effective application Changeable tips for a maximum effect and personalization Top results, no downtime Non-invasive → Painless → Instant glow → No downtime Immediate confidence Accessible price point BEAUTYHEALTH™#2626 Source: Company data as of 2022. Confidence builder Priority, not discretionary Devoted community of aestheticians & consumers 44 NPS, best in class Compelling & differentiated treatment Category-creating, patented and efficacious product Hydrafacial Growth Flywheel Favorable economics High-profit treatment for providers; dual revenue stream for Beauty Health Connected digital platform Data insights for consumer customization, provider business optimization Ecosystem of co-creators Fellow skin experts 10 BEAUTYHEALTH™#27Treatments personalized every time with our range of boosters 3 + 14 = Hydrafacial Partner developed boosters boosters 27 Mura a zapomanda RETINOL BOOSTER Delivered by HydraFacial™ POURT Net 9 ml / 0.30 R or US Layering combinations Note: Figures include J Lo Beauty booster launching in fall 2022 and exosome booster launching in 2023. Alpha-Arbutin & Vitamin C Brightening Solution ! BRITENUL™ Acvanced Age Refiring Postide Comp ex Solution Nourishing products designed for individual skin health goals ! DERMABUILDE Skin Perfecting Protein Solut Re Gen GF™ BRITENOL Helps minimize the appearance of dark spots and helps balance skin tone DERMABUILDER Helps smooth the appearance of fine lines and wrinkles and enhances skin elasticity REGEN GF Helps maintain the appearance of healthy and youthful looking skin and supports hydration BEAUTYHEALTH™#28with fellow skin experts reach Boosters co-created expand our R&D and HYDRAFACIAL ROZATROL" BOOSTER SERUM SERUM REVITALISANT ROZATROL HYDRAFACIAL 9mL/ Net 0.30 Fl. Oz. U.S. FOR PROFESSIONAL USE ONLY, NOT FOR RESALE. SINGLE USE; DO NOT REFILL DESTINE & UN UTILISATION PROFESSIONNELLE UNIQUEMENT NON DESTINE A LA REVENTE A USAGE UNIQUE: NE PAS RECHARGE. po roma dapy cararga m HYDRAFACIAL BRIGHTALIVE" BOOSTER SERUM SERUM SUBLIMATEUR HYDRAFACIAL BRIGHTALIVE 9 m/Net 0.30 Fl. Oz. U.S. FOR PROFESSIONAL USE ONLY, NOT FOR RESALE. SINGLE USE; DO NOT REFILL IN A LINE UTUSARON PROFESSIONPLIFUNIGUEMENE NON DESTINE A LA REVENTE A USAGE LINGUE NE PAS RECHARGER HOME PROTETOR 0.3 fl oz/9 mL Powered by SENTE"'s patented HSA (Heparan Sulfate Analog) 9mL/0.30 FL OZ SENTÉ HydraFacial Dermal Repair Booster NASSIFMD Murad. HYDRAGLUCAN™ Delivered by HydraFacial Net 9 ml / 0.30 l. oz. U.S. Dadilly CCC. Andadion FOR PROFESSIONAL USE ONLY, NOT FOR RESALE. FOR PROFESSIONAL USE ONLY, NOT FOR RESALE. CLARIFYING BOOSTER Delivered by HydraFacial Murad. VITA-C BOOSTER Delivered by HydraFacial™ FOR PROFESSIONAL USE ONLY, NOT FOR RESALE. SINGLE USE; DO NOT REFILL. DIRECTIONS AND INGREDIENTS: Use only as directed.. Modo in the USA Cestand MERAD RETINOL BOOSTER Murad. Delivered by HydraFacial™ FOR PROFESSIONAL USE ONLY, NOT FOR RESALE. SINGLE USE; DO NOT REFILL. DIRECTIONS AND INGREDIENTS: Use only os directed. A propo Pml / 0.3 11 az Net 9 ml/0.30 or US Delivered by HydraFacial 9 ml / Net 0.30 fl oz U.S. POWER SERUM Tour & Net 9 ml / 0.30 fl oz U.S. Net 9 ml / 0.30 fl oz U.S. Delivered by Hydrafacial™ NECK AND DÉCOLLETÉ BOOSTER VITAL DEFENSE BOOSTER PROTEC PLUS 9 ml / Net 0.30 Fl. Oz. U.S. Net 9 ml / 0.30 fl oz U.S. HydroPeptide anorreciONUL Lee ONLY NOT FOR DEALE by MLADI EPICUTIS.. FOR PROFESSIONAL USE ONLY. NOT FOR RESALE i FOR PROFESSIONAL USE ONLY. NOT FOR RESALE SKIN ENERGIZING BOOSTER I CHRONO-PEPTIDE Delivered by HydraFacial TRIHEX-PRO QA Flexibility to feature leading technologies on our platform BEAUTYHEALTH™ Note: J Lo Beauty booster and exosome booster not pictured. 28#29At the forefront of innovation: exosome booster What are exosomes? Extracellular vesicles carrying cell-specific cargos of cytokines, chemokines, and growth factors → Exosomes are involved with cellular communication with respect to repair and regeneration and can address the signs of inflammation and aging 29 Expected launch in 2023 Photo: Guillaume Pelletier, CC BY-SA 4.0 <https://creativecommons.org/licenses/by-sa/4.0>, via Wikimedia Commons. VEY CHEE BEAUTYHEALTH™#30Our regenerative economic model 3 Consumables re-ordered 30 1 Delivery system purchased 2 Hydrafacial performed Syndeo (U.S.) hydrafacial Tips O Elite (ex-U.S.) JEAESE Solutions EXTRACT binder MINE ! VORATE ad.dep Vrante Perk 1 REISE Intrate Allegro BRITENOL SITA Boosters DERMABUILDER 1.20 TORS hydrafacial 0 ReGen GE 2 HAL + Co-branded partnerships BEAUTYHEALTH™#31Our dual revenue streams are nearly equally split, with a recurring element in consumables 31 hydrafacial ! EANSE indical EXTRACT stradal ! ANTIOX- SEAWAY Misbacal 18/3 Delivery systems 54% FY 2021 net sales Consumables 46% FY 2021 net sales BEAUTYHEALTH™#32Our 5-point master plan to drive transformative growth 32 0 C 20 Expand footprint Invest in providers Drive brand awareness Build global infrastructure M&A BEAUTYHEALTH™#335-point master plan 33 0 C 20 Expand footprint Gub Invest in providers Drive brand awareness Build global infrastructure KT M&A BEAUTYHEALTH™#34Clear runway to expand -5% global penetration Low teens % Penetration in the Americas -1% Penetration in APAC LDD% Penetration in EMEA 34 Source: McKinsey & Company feasibility analysis (2022), management estimates. BOARDWA BEAUTYHEALTH™#35GLASS PETER CROFETY FREE LUXURY BEAUTY TOENSIER Deepening our foothold in medical and spa, and penetrating new channels SEPHORA 35 FOT DIOR PAT MOCRATH LABS tarte Wp-produk SHAPETAPENATION Makeup ESTRE VALDER LANKON SEPHORA intemp NA COLLECTION FRASER BENAR ORIGINI www DAGLE H LANCOME Skincare ESTEE LALERM REPHORI Retail Expanding to Sephora APAC in September 2023 SEPHORA SEPHORA BEAUTYHEALTH™#36Syndeo's launch has been next-level 3x Sales Exceeded month 1 launch expectations -2,265 Systems In market¹ 2023 Expansion To EMEA and APAC 36 1. As of June 30, 2022. 18 BEAUTYHEALTH™#375-point master plan 37 0 FO Expand footprint Invest in providers Drive brand awareness Build global infrastructure KT M&A BEAUTYHEALTH™#38HFX is the world's no. 1 educator of aestheticians 38 25 35,000+ Aestheticians trained hydrafacial hydrafacial Los Angeles Chicago ST NYC Dallas Mexico City London Now Paris! Frankfurt Madrid Shanghai 13 Experience Centers Tokyo Now Singapore! Sydney BEAUTYHEALTH™#39We invest in our providers at events and trade shows Ankaral 39 hydrafacial IECSC Las Vegas, NV, USA | June 2022 hydrafacal NAT Infocal (AIS INNOVATION Beauty Fair Düsseldorf, Germany | May 2022 hydrafacial alacal AIS San Diego, CA, USA | April 2022 SUMMIT hydrafacial ydrafacial WHEFF draforgal hydraa LIES Uber do W ope PIRTY 30% za 2X Twóraldavad F Lerhed Five Jabral co DAY TO MINUTES. For the most delicate areas of face AMWC Monaco | April 2022 IMCAS Paris | June 2022 Petalizad STEP 1 CLEANSE+PEEL STEP 2: EXTRACT HYDRATE STEP 3: PROTECT ydrafac BEAUTYHEALTH™ OF TURUE#40We help providers build their businesses Physician Spa owner 40 hydrafacial Creates a profitable gateway MDs and spas see more gross profit per Hydrafacial than for the leading neurotoxin Attracts a higher income consumer typically purchasing two or more aesthetic treatments Source: Company data. Retailer TOAT and Drives traffic Retailers report higher average basket size for consumers receiving Hydrafacial instore Solo practitioner Anchors the practice A solo practioner performing just 10 Hydrafacials per week earns $100,000 annually BEAUTYHEALTH™#4141 hydrafacial N We are rewarded with a deeply passionate community of providers, our Hydrafacial Nation BEAUTYHEALTH™#425-point master plan 42 0 FO Expand footprint Invest in providers Drive brand awareness Build global infrastructure Con M&A BEAUTYHEALTH™#43Galvanizing influencers at every level Trust Reach 43 MDS Aestheticians Skinfluencers Celebrities Data as of September 2022. NASSIFMⓇD @jadeywadey180 IG 1.2M pfrank By Dr. Paul Jarrod Frank @laurenluyendyk IG 1.2M Kim Kardashian IG 328M @miracletheesti TT 732K @iamkaylanicole IG 640K Jennifer Lopez IG 220M @thedallasaesthetician IG 220K @tinachencraig IG 511K Paris Hilton IG 20M BEAUTYHEALTH™#4444 MERVER 010 JLO BEAUTY Han JLO BEAUTY' Delvered By hydrafacial LO BEAUTY BOOSTER LEADEN UKUMN BEAUTYHEALTH#455-point Master Plan 45 0 FO Expand footprint CES Invest in providers Drive brand awareness Build global infrastructure GET M&A BEAUTYHEALTH™#46Innovating to deliver a head-to-toe glow Neck Décolleté Back The face is only 3.5% of total skin surface¹ 46 1. Wolf SE, Prnitt BA., Jr. Burn management. In: Irwin RS, Rippe JM, editors. Irwin & Rippe's intensive care medicine. 6th. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. Figure 129-1, pp. 1930. Booty BEAUTYHEALTH™#47Building a revolutionary scalp & hair opportunity with Keravive Treatments administered by doctors and medi-spas are the fastest growing segment of the $4.9bn Hair restoration market HYDRAFACIAL KERAVIVE Peptide Comel hydrafacial™ keravive. 47 1. Grand View Research Hair Restoration Market Size, Share & Trends Analysis Report. COMPLETE KIT COFFRET COMPLET Contain: Two (2) wish of 0.38 2/9 ml each one (1) spray of 3.4/100 ml, and one (1) tent to (20 foles de 9 ml/9.3.8. chacune, un (1) HYDRAFACIAL KERAVIVE™ Peptide Complex Solution for Scolp Health hydrafacial keravive. PEPTIDE COMPLEX SPRAY FOR SCALP HEALTH 3.4 fl oz/100 ml Part of the Hydrafacial family. 3 steps to healthy, fuller-looking hair. Cleanse, exfoliate, hydrate. Tiny molecules, big results. Proprietary blend of biomimetic polypeptides and skin proteins. BEAUTYHEALTH™#48Developing and validating the at-home category Global at-home beauty device market set to grow 10x, reaching $90.5bn by 2030' 48 1. P&S Intelligence Home-Use Beauty Devices Market Research Report (September 2021). BEAUTYHEALTH™#49Our ESG journey has just begun 49 Products Distribution MINDFULLY People MADE Partnership BEAUTYHEALTH™#505-point master plan 50 0 FO Expand footprint CES Invest in providers Drive brand awareness Build global infrastructure M&A BEAUTYHEALTH™#51Accelerating the Beauty Health platform through M&A Differentiated product or service / high Net Promoter Score Complementary to our existing platform and community, leveraging the trusted aesthetician Financially attractive profile via compelling revenue growth, recurring revenue characteristics, and / or profitability 51 Beauty Aesthetics Wellness Health BEAUTYHEALTH™#52Our M&A philosophy 52 Identify gaps in bundle Integrate and realize synergies Acquire digestible asset No predetermined timeline for transaction - opportunistic philosophy rather than time-based BEAUTYHEALTH™#5353 Our three-year plan BEAUTYHEALTH#54Our three-year plan is expected to drive meaningful profitable growth 2x net sales vs. 2022E 54 3x+ Adj. EBITDA vs. 2022E $600 - $700mm 18 - 20% 2025E net sales 20-27% 2022E - 2025E CAGR¹ 25-30% 2023E Adj. EBITDA margin 2025E Adj. EBITDA margin Note: Adjusted EBITDA is a non-GAAP measure. See appendix for a definition and discussion. Our achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in our filings with the SEC. The plan does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of our acquisitions, dispositions or financings during 2022. Our plan assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented; 1. Assuming midpoint of previously stated 2022 $340-350mm net sales guidance. BEAUTYHEALTH™#55Why I am confident in our plan 55 Personalised Skin Health by hydrafacial 1 7 Scalable and profitable operating model MA 2020 2021 2022 fim 100% 80% Consistent track record of growth and margins CITY TAKEOVI ydrafacial GLOWVOLUTION TO WA OR SAN FRANCISCO DRIVE BY LOS ANGELES NV ID LAS VEGAS SAN DIEGO UT AZ MT PHOENIX DES DE Massive, resilient and growing market opportunity VOTR ydrafad Desirable and committed consumer and provider community Ample liquidity and prudent capital allocation Best-in-class management team BEAUTYHEALTH™#56Today's agenda The road to BeautyHealth 56 Brent Saunders Executive Chairman Q&A The future of Beauty Health Andrew Stanleick President & Chief Executive Officer Closing remarks Andrew Stanleick President & Chief Executive Officer Ben Baum Chief Experience Officer Delivering the three-year plan Building brand love Liyuan Woo Chief Financial Officer Clinical approach behind the Hydrafacial glow Jwala Karnik, MD EVP of Global Strategy & Partnerships Fireside chat: power of an omni-channel strategy Jwala Karnik, MD Mingo Ku EVP of Global President, Strategy & Partnerships North Asia Dan Watson EVP, Sales Americas Break BEAUTYHEALTH™#5757 Building brand love Ben Baum Chief Experience Officer BEAUTYHEALTH#58Hydrafacial Nation: at the heart of all we do hydrafacial 58 tal jan hydrafacial 199 fiscal hydrafacial Providers S hydrafacial CUDAL ini at Th VIVAC hydrafacial hydrafacial For €3253 30 SUND TOX- AWAY hydrafacial SPAIN hydrafacial BEAUTY IS FEELING hydrafacial BEAUTY IS A FEELIN I Consumers yu BEAUTYHEALTH™ Cia#5959 DSET IS NG Our providers The core of our engine hydrafacial PRESSR BEAUTYHEALTH™#60DERMA hy The Golden Triangle of support and education AC GLYSAL PREP ! Beautiful afacialNation 60 BRITEN והטות. hydrafacial hydrafacial DERMABUILDER THE BEST SKA OF MANLIFE Marketing Sales FAC FACE 11 vd FACE LIFE FACE FIRST hydrafacia THE BEST SON OF YOUR LIFE STARTS Training BEAUTYHEALTH™#61We offer a comprehensive portfolio of education services 61 afacia THE BEST DEN OFVING LIFE STAACS hydrafacial 海秀 hydrafacial 唤醒肌肤 【源动力 As of September 2022. Mal Cial Aptekaryd art Cia iptabl Ipatiyal d Inland 海菲秀 等你来秀 af Ap ble wed WA hidal CONNECT HYDRAFACIAL CERTIFIED PROFESSIONAL CONNECT CO CERTIFIED EXPERT HYDRAFACIAL CONNECT CO CERTIFIED MASTER 13 HFX Experience Centers 75+ Schools with Hydrafacial presence 35,000+ Aestheticians trained BEAUTYHEALTH™#62The result: providers as Hydrafacial brand evangelists and delighted clients 62 hydrafacial ESPALOBZA KHIM ESTIPALOOZA #GUN #GUNKIE Hydrafacial has filled in every missing piece in our medical spa. Not only did it attract new clientele, our retention rate grew to 92% after our first 5 months. It has enabled us to increase our sales with other services, especially laser treatments, where we've had tremendous results and growth since introducing Hydrafacial. - Provider, Rhode Island hydrafacial II BEAUTYHEALTH™#6363 hydrafacial STA BUTER FACI Personalised Skin Health by hydrafacial ! HYDRATE Our consumers The ultimate beauty health enthusiasts BODY InS BEAUTYHEALTH™ A 0#64Reaching the coveted Hydrafacial consumer #GUNKIE #GUNKIE #GUNKIE 64 #GUNKIE $94,000 Average HH income #GUNKIE 30s Average age 92% Hydrafacial consumers would switch aestheticians if they did not offer Hydrafacial Source: Company data. >20% Men 8% Aided brand awareness 44 Consumer NPS COME 33% Latinx consumers Life Events Biggest purchasing driver 94% feel more confident after Hydrafacial BEAUTYHEALTH™#65Aided brand awareness 65 95% BOTOX® 2019 45% OLAPLEX. 2021 Source: Company data, company filings, Google. 8% hydrafacial 2022 BEAUTYHEALTH™#66Galvanizing influencers at every level Trust Reach 66 MDS Aestheticians Skinfluencers Celebrities Data as of September 2022. NASSIFMⓇD @jadeywadey180 IG 1.2M pfrank By Dr. Paul Jarrod Frank @laurenluyendyk IG 1.2M Kim Kardashian IG 328M @miracletheesti TT 732K @iamkaylanicole IG 640K Jennifer Lopez IG 220M @thedallasaesthetician IG 220K @tinachencraig IG 511K Paris Hilton IG 20M BEAUTYHEALTH™#67Growing brand awareness Worldwide Google search trends Interest Over Time 67 100 90 80 70 60 50 40 30 20 10 0 Jan-19 2022 YTD Avg wwwwww прими личным Sep-19 Jun-20 Mar-21 Dec-21 Aug-22 +36% vs. August 2019 YTD +28% vs. August 2021 YTD Source: Google, Tribe Dynamics. Earned media value ($K) $4,271 Aug-19 YTD $5,623 Aug-21 YTD $7,964 Aug-22 YTD +86% vs. August 2019 YTD +42% vs. August 2021 YTD BEAUTYHEALTH™#6868 b hydrafacial ¡ Our product Designing the future of beauty health BEAUTYHEALTH™#6969 hydrafacial ! Personalize Your Treatment SCAN OR CODE Select a Treatment ! hydrafacial ! HYDRATE ! Explore Treatment Options EXPLORE OPTIONS Park Fre e Meet Syndeo The future of skin health reimagined. °° O Elevated design Enhanced ease-of-use and intuitive operation Co-created with aesthetician partners Connected experience BEAUTYHEALTH™#70Syndeo will pave the way to our connected platform First of its kind smart delivery system Ultimate in ease-of-use and intuitive operation Data to optimize utilization Closed loop Connected consumer loyalty program to grow repeat visits and LTV Global expansion 70 (Edit Treatment Delove Hydrofacial Exfoliation Instructions andp reded Adual vocam ating de dab and not the lo pasto mo s Use king for 005 overlappingstokes Moke pasies for complene olanor Hod Device Handpieos Tip hydrafacial Serum Acky -4 ACTIV 4 Treatment Patter Dabar Owinpoker WHETSAR Step 1 Step 4 Step 2 ******* BETA HD CLEAR Step 3 ANTIOX+ RINSEAWAY 4 1433 Vacuum 14 9 BEAUTYHEALTH™#71Poised for growth and future success 71 2 3 Our Golden Triangle cultivates a loyal and engaged community The Hydrafacial consumer is highly desirable Syndeo offers opportunity to spin our flywheel faster hydrafacial BULUT DBEAUTYHEALTH bydrafacial AMGI TOY Adrfa BEAUTYHEALTH hydrafacial SHYGRAFAQALINY HYDRAFACIAL COOK BEAUTYHEALTH™#7272 Behind the Hydrafacial glow Jwala Karnik, MD EVP of Global Strategy & Partnerships BEAUTYHEALTH#73Skin health 101 73 Epidermis Dermis BEAUTYHEALTH™#74Skin health 101 74 Epidermis Dermis BEAUTYHEALTH™#75Our magic wand: patented handpiece & tip Spiral tip gently, but effectively, abrades epidermal layer →Patented vortex technology helps dilate pores to facilitate extraction of dirt, sebum, and keratinocytes with continued improvement over time 75 Proprietary vortex technology Advanced serum delivery Patented spiral design with multiple abrasive edges BEAUTYHEALTH™#76Wand as a platform 76 Murad. RETINOL BOOSTER by S RETINOL BOOSTER Murad. hydraf SCA GOSS NASSIFMD hydrafacial VITAL DEFENSE B !PROTEC F AL USE ONLY. NOT FOR RESALE VITAL DEFENSE BOOSTE PLUS PROTEC 1 000 ·lolox Booster partners QALASTIN OSKINCARE P CIRCADIA HydroPeptide® Organicell Murad. NASSIFMD DERMACEUTICALS® XXXX restørsea Senté JLO BEAUTY™ ZOⓇSKIN HEALTH BEAUTYHEALTH™#77At the forefront of innovation: exosome booster What are exosomes? Extracellular vesicles carrying cell-specific cargos of cytokines, chemokines, and growth factors → Exosomes are involved with cellular communication with respect to repair and regeneration and can address the signs of inflammation and aging 77 Expected launch in 2023 Photo: Guillaume Pelletier, CC BY-SA 4.0 <https://creativecommons.org/licenses/by-sa/4.0>, via Wikimedia Commons. VEY CHEE BEAUTYHEALTH™#78The multiple mechanisms of action for Hydrafacial Reduction vs. Baseline in dirt and sebum post-Hydrafacial 78 Week 2 Week 8 (35%) Dirt (95%) Sebum (39%) (95%) Source: 2017 study conducted by Dermatology Consulting Services and commissioned by Hydrafacial; results shown in conjunction with a ZO Skin Health protocol including bi-daily cleansing and scrubbing in addition to a daily scrub. BEAUTYHEALTH™#79The multiple mechanisms of action for Hydrafacial Investigator assessment of hydration and moisturization post-Hydrafacial Week 2 79 Week 8 +26% +83% Moisturization +20% +70% Hydration Source: 2017 study conducted by Dermatology Consulting Services and commissioned by Hydrafacial; results shown in conjunction with a ZO Skin Health protocol including bi-daily cleansing and scrubbing in addition to a daily scrub. MO19# LEXIC BEAUTYHEALTH™#80The multiple mechanisms of action for Hydrafacial Mean improvement from baseline score in efficacy variables post-Hydrafacial Control Epidermal thickness (μm) 49 ± 7 Papillary dermal thickness (μm) 80 285 ± 20 Post skin regimen + Hydrafacial 80±8 418 ± 25 Source: Bruce M. Freedman (2009) Topical antioxidant application enhances the effects of facial microdermabrasion, Journal of Dermatological Treatment, 20:2, 82-87, DOI: 10.1080/09546630802301818. BEAUTYHEALTH™#81Hydrafacial delivers positive patient reported outcomes Mean improvement from baseline score in efficacy variables post-Hydrafacial 81 Dona Pore size Fine lines Texture Hyperpigmentation Dullness Hydration 0 0.5 1.5 Changes from baseline (mean score) 1 Statistically significant improvement in hydration Source: Bruce M. Freedman (2009) Topical antioxidant application enhances the effects of facial microdermabrasion, Journal of Dermatological Treatment, 20:2, 82-87, DOI: 10.1080/09546630802301818; p < 0.01. Statistically significant reductions 2 BEAUTYHEALTH™#82While also improving outcomes for other treatments 30% Additional reduction in brown spots when added to Intense Pulse Light (IPL) therapy 82 Source: Company data. 50% Smoother skin when used with ablative fractional lasers 2x Firmer and smoother skin when paired with non-ablative fractional laser or fractional RF & love! 2x Smoother skin when used with RF or focused ultrasound BEAUTYHEALTH™#83Most importantly, Hydrafacial creates happy, confident consumers 83 CIND JUST GOT MY cial RAFACIAL SKIN OF YOUR LIFE hydrafacial EXA BEAUTYHEALTH™#84Most importantly, Hydrafacial creates happy, confident consumers 84 Source: Company data. CIND cial 94% Users reporting a confidence boost after their last Hydrafacial RAFAVIML SKIN OF YOUR LIFE hydrafacial BEAUTYHEALTH™#85And satisfied providers 85 ASS How THE BEST SKIN OF YOUR LIFE STARTS THE BEST SKIN OF YOUR LIFE STARTS 1 THE BEST SKI OF YOUR LIFE STARTS TUN HydraFacial MD We BEAUTYHEALTH™#86Key takeaways 86 2 3 Patented Hydrafacial technology yields efficacious, instantly gratifying results Wand serves as a unique delivery platform for a range of personalized offerings Our booster strategy is a unique and agile innovation engine dat BEAUTYHEALTH™#87Jwala Karnik, MD EVP of Global Strategy & Partnerships 87 Mingo Ku President, North Asia Fireside chat: Power of an omni-channel strategy Dan Watson EVP, Sales Americas BEAUTYHEALTH#88We help providers build their businesses Physician Spa owner 88 hydrafacial Creates a profitable gateway MDs and spas see more gross profit per Hydrafacial than for the leading neurotoxin Attracts a higher income consumer typically purchasing two or more aesthetic treatments Source: Company data. Retailer TOAT and Drives traffic Retailers report higher average basket size for consumers receiving Hydrafacial instore Solo practitioner Anchors the practice A solo practioner performing just 10 Hydrafacials per week earns $100,000 annually BEAUTYHEALTH™#8989 Fireside chat: Power of an omni-channel strategy BEAUTYHEALTH™#90Hydrafacial contributes to practice productivity Suggested price per treatment Cost of consumables Gross profit to provider Gross margin to provider TEU 90 Note: Indicative values based on management data and estimates. Express -$150 - $200 -$25 – $35 -$115 - $175 -76% -88% 13 Platinum -$300 - $500 -$30 – $35 -$265 - $470 -88% – 94% Body treatment -$2,800 -$250 -$2,550 -90% HydraFacial MO BEAUTYHEALTH™#9191 Fireside chat: Power of an omni-channel strategy BEAUTYHEALTH™#92We deliver diversified net sales regionally % net sales, FY 2021 92 Americas 65% EMEA 18% APAC 17% BEAUTYHEALTH™#9393 Fireside chat: Power of an omni-channel strategy BEAUTYHEALTH™#94Key takeaways 94 2 3 Medical channel is showing continued strong growth as our core Spa and hospitality will continue to grow behind aesthetic boom Retail offers an opportunity to drive brand awareness and trial International markets outside of U.S. are showing explosive growth Please CT AVING BEAUTYHEALTH™#9595 OBROL Delivering the three-year plan Liyuan Woo Chief Financial Officer BEAUTYHEALTH#96Agenda 96 2 3 Our unique positioning and track record of success Understanding our business Three-year plan hydrafacial IF YOU KNOW, YOU GLOW hydrafacial BEAUTYHEALTH™#97hydrafacial 97 Our unique positioning & track record of success 2 3 BEAUTYHEALTH™#98Hydrafacial offers unique competitive strengths Asset-light, high margin. profitable growth Patented technology & compelling clinicals 98 MI Complementary with other treatments hydrafacial Engaged community/ flywheel Agile marketing supporting Golden Triangle Large and nascent TAM - 4 88 BEAUTYHEALTH™#99Uniquely positioned amidst medtech peers 2021 EBITDA Margin 99 70% 60% 50% 40% 30% 20% 10% 0% 0% 20% $5.3bn mkt cap $2.6bn mkt cap 40% $2.9bn mkt cap 60% Few medtech companies with better margin and growth profile 80% 100% 2018-2022E Revenue CAGR Source: FactSet as of 09/04/22; includes all publicly traded MedTech companies with a market cap $1bn+ traded on US-based exchanges. 120% 140% 160% 180% BEAUTYHEALTH™#100100 Macro tailwinds are with us, and consumer demand is all-weather Tailwinds Societal shift toward health and wellness Broader definition of beauty: embrace your version of beauty, whatever that may be Reduced stigma, increased access, and advances in aesthetic procedures Post-pandemic Zoom boom: our face is our business card Headwinds Geopolitical uncertainty Macroeconomic environment COVID-19 lockdowns Supply chain disruptions CCCC SEPHORA CCOO COCO PC C C C C C BEAUTYHEALTH™#101Significant recent accomplishments 101 52%¹ 2018-2021 net sales CAGR 6 Consecutive topline beat and raise quarters $750 million 1.25% Convertible debt opportunistically raised 70 / 74% 2021 gross margin / adjusted gross margin² 4 Distributor acquisitions completed in 2021 Global ERP Implemented by YE 2022 1. Excludes 2020 due to pandemic impact. 2. Non-GAAP measure; please refer to the appendix for a discussion of the definition of this measure and a reconciliation to the nearest GAAP measure. 8 0 ☐ hydrafacial 0 ☐ SKIN Nasdaq Listed L 1 1 Nasdaq BEAUTYHEALTH™#102Consistently beating and raising expectations Strong track record of net sales outperformance ($mm) Consensus estimate $49.2$66.5 $58.0$68.1 $83. $$103.5 $44.1 $47.5 1021 102 +7.8% $181 Dec-20 Net sales outlook ($mm) $200 2021 May-21 +35.2% $235 Source: FactSet consensus estimates. 3021 2021 Outlook +17.5% $250 Aug-21 Nov-21 $260 2021A Net sales $71.1 $77.9 4021 +9.5% $250 Dec-20 $68.1$75.4 1022 +10.7% $320 - $330 - $330 $340 Feb-22 May-22 2022 Outlook 2022 (+23.4%) $340 - $350 Aug-22 hydrafacial IF YOU KNOW, YOU GLOW BEAUTYHEALTH™#103Dollar EBITDA guidance as we scale Historical adjusted EBITDA outlook ($mm) 103 $25 2021 Outlook (12/20) $25 2021 Outlook (05/21) $30 2021 Outlook (11/21) $33 2021 Actual $50 2022 Outlook Note: Adjusted EBITDA is a non-GAAP measure; please refer to the appendix for a discussion of the definition of this measure and important information regarding the assumptions underlying the outlook. hydrafacial™ COMPANY BEAUTYHEALTH™#104$821 million Cash to fuel M&A $50 million Senior Secured Credit Facility to manage working capital Ample inventory to meet demand 104 Well capitalized to execute Data as of 06/30/22. hydrafacial hydrafacial BEAUTY IS A FEELING BEAUTYHEALTH™#105105 prilalfacial 0 Understanding our business 1 2 3 BEAUTYHEALTH™#106Seasonality in the business - 2019 example % of 2019 net sales and adjusted EBITDA generated by quarter¹ 21% 1019 15% 25% 2019 24% 24% 3019 25% 30% Net Sales 106 1. Non-GAAP measure; please refer to the appendix for a discussion of the definition of this measure and important information regarding the assumptions underlying the outlook. 36% Adj EBITDA 4019 Q4 is typically the biggest quarter of the year; we invest heavier in first half of the year BEAUTYHEALTH™#107Understanding sequential net sales growth patterns Sequential net sales growth by calendar quarter 50% 40% 30% 20% 10% 0% (10%) 107 Slight sequential decline vs. 4Q - returns from vacation, recently completed capex cycle 10 -2019 Increase vs. 1Q as leads convert 20 2021 -2022 30 1 Holiday promotions and capex budget exhaustion lead to highest $ net sales quarter of the year Summer seasonality impact 4Q BEAUTYHEALTH™#108Consumables keeping pace with accelerated system sales Net sales ($mm) $34.7 51% 49% 108 $42.3 51% 49% 1019 2019 3Q19 Delivery systems sold 4,103 3,943 2019 160 ■Delivery Systems Trade-Ups¹ Consumables (Excludes value of training kits included) $39.6 52% 48% 1. Trade-Up revenue only disaggregated in 2022. $49.9 51% 49% 4019 2,647 2,602 2020 $47.5 46% 54% 1021 45 $66.5 47% 53% 2021 $68.1 47% 53% 3021 +51% vs. 2019 6,191 5,950 New Systems Trade-Ups 2021 $77.9 45% 55% 4021 241 $75.4 45% 55% 1022 $103.5 37% China, Syndeo 23% & geopolitical 40% impact 2022 +65% vs. 21YTD 4,587 1,461 3,126 1H2022 BEAUTYHEALTH™#109Quarterly net sales by region $34.7 5.8 26.5 2.5 1019 76% 7% 17% $42.3 7.8 31.8 2.8 2019 75% 7% 18% $39.6 6.5 29.8 3019 75% 8% 16% 3.3 109 1. Excludes $23.3 million net sales associated with trade-ups during 2022. Americas APAC EMEA Trade-Ups $49.9 8.4 7.3 34.2 $47.5 7.5 8.8 4019 69% 15% 17% 31.3 $66.5 11.4 12.4 1021 66% 18% 16% 42.7 $68.1 12.6 10.5 45.0 $77.9 15.5 3021 66% 15% 19% 12.0 50.4 $75.4 4021 65% 15% 20% 17.9 % Net sales 2021 Americas 64% APAC 19% EMEA 17% Moving from 70% Americas / 30% APAC+EMEA to 60% Americas / 40% APAC+EMEA without impact from China 12.9 44.6 $103.5 1022 59% 17% 24% ¹23.31 17.8 10.4 52.1 $80.2¹ 2022 73% 10% 17% BEAUTYHEALTH™#110Understanding quarterly adj. EBITDA margin patterns Adjusted EBITDA margin¹ by calendar quarter 30% 25% 20% 15% 10% 5% 0% COVID impact led to scale back in usual 1H selling & marketing spend 10 -2019 20 2021 Step-up in margin 2Q vs. 1Q -2022 Seasonal summer slowdown leads to reduced operating leverage 30 110 1. Non-GAAP measure; please refer to the appendix for a discussion of the definition of this measure and a reconciliation to the nearest GAAP measure. 40 is traditionally highest margin quarter COVID re-openings led to higher than usual 4Q selling & marketing spend 40 Heavy marketing investments are usually in first half of the year to fuel leads for the year BEAUTYHEALTH™#111111 hydrafacial Collecon Syst CE GCT THAT hydrafacial GLOWolution AUTY IS Three-year plan 1 2 3 BEAUTYHEALTH™#112Our three-year plan Double net sales (vs. 2022) $600 - 700mm 2025E net sales 20 - 27% 2022E - 2025E CAGR¹ 112 Continued penetration across all channels Nascency across key geographies Consumables pull-through Note: Our achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in our filings with the SEC. The plan does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of our acquisitions, dispositions or financings during 2022. Our plan assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented; 1. Assuming midpoint of previously stated 2022 $340-350mm net sales guidance. BEAUTYHEALTH™#113Our three-year plan At least triple adjusted EBITDA (vs. 2022) 18 - 20% 2023E Adjusted EBITDA margin 113 25 - 30% 2025E Adjusted EBITDA margin Value engineering efforts creating gross margin expansion Shift mix towards consumables → Operating leverage across the expense base Note: Adjusted EBITDA is a non-GAAP measure. See appendix for a definition and discussion. Our achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in our filings with the SEC. The plan does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of our acquisitions, dispositions or financings during 2022. Our plan assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented. BEAUTYHEALTH™#114Balancing growth with profitability Net sales growth 20% 30% - 50%+ 18-20% Net sales growth Adjusted EBITDA margin¹ 30% 25% Adjusted EBITDA margin 2023E 2025E Striking the right balance to optimize in the U.S. while fueling growth globally 1. Non-GAAP measure; please refer to the appendix for a discussion of the definition of this measure and important information regarding the assumptions underlying the outlook; Note: Our achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in our filings with the SEC. The plan does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of our acquisitions, dispositions or financings during 2022. Our plan assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented. 114 BEAUTYHEALTH™#115Our 5-point Master Plan expected to support continued growth momentum 6600 115 Expand Footprint →Place systems in a profitable landgrab ose to'p Invest in Providers →Education and events to fuel sales conversion Drive Brand Awareness Agile marketing to increase engagement and utilization Build Global Infrastructure Scale profitable growth G M&A → Accretive M&A to add product offerings and capabilities BEAUTYHEALTH™#116We are playing in a large, high-growth market Estimated number of locations in our direct markets Dermatology offices Plastic and aesthetic surgery offices Medical spas Non-medical spas Hotel / resort spas Higher-end gyms / studios Total doors Penetration 116 Americas 15,500 10,000 11,000 9,500 32,000 21,000 99,000+ Low teens % Total APAC EMEA 25,500 8,500 49,500 Source: McKinsey & Company feasibility analysis (2022), management estimates. 8,500 80,500 109,000 54,000 16,000 293,500+ -1% 11,000 2,000 10,500 17,500 2,500 52,000+ LDD % 29,500 93,500 129,000 103,500 39,500 444,500+ -5% Upside drivers Excludes indirect markets Excludes multiple systems in each location Excludes upside from additional penetration in retail Excludes travel (cruises, airports) Huge TAM and underpenetrated even in the highest utilization areas of spas BEAUTYHEALTH™#117Compelling growth profile - current state Net sales ($mm) % net sales Americas APAC EMEA $112.3 Americas APAC EMEA 2018 79% 6% 15% 1021 18% 252% 29% Quarterly sales growth by region¹ 2021 34% 352% 46% $166.6 117 1. 2021 quarters compared to respective 2019 quarters due to COVID. Note: Percentages may not recalculate due to rounding. 2019 73% 9% 17% Delivery Systems Consumables 3021 51% 218% 94% $119.1 2020 68% 12% 19% 4Q21 47% 64% 85% $260.1 2021 65% 17% 18% 1022 43% 47% 140% $179.0 1H 2022 67% 13% 20% 2022 77% (17%) 56% COVID impact BEAUTYHEALTH™#118APAC and consumables are key drivers of growth Net sales by geography Americas APAC EMEA Net sales by segment 118 Delivery Systems Consumables 17% 46% 18% 2021A $260.1mm 2021 net sales $260.1mm 2021 net sales 65% 54% 2025E $600 - 700mm 2025 net sales >50% EX-U.S. $600 - 700mm 2025 net sales >50% Consumables BEAUTYHEALTH™#119Levers to increase utilization 119 Account management Branding and education initiatives +6-40x ROI on marketing 2 - 4X return on training Trained masters generate 20% more consumable revenue Connected and personalized CRM tools for account managers Source: Company data. Branding investment hydrafacial IF QV b₁ PEPTIDE G BOOSTER ww Drive boosters GLYSALT F Powered by SENTE HydraFacial De 7229 Extend beyond the face mb Hands Scalp Décolleté Lips Back Booty BEAUTYHEALTH™#120Returning to and exceeding historical adj. EBITDA margins Adjusted EBITDA margin by calendar year¹ 30% 25% 20% 15% 10% 5% 0% $32.7mm Adj. EBITDA $50mm Adj. EBITDA 18 - 20% 2023E Adj. EBITDA margin 1 1 25% - 30% 2025E Adj. EBITDA margin 2018 2019 2021 2022E 2023E 2024E 2025E 1. Non-GAAP measure; please refer to the appendix for a discussion of the definition of this measure and important information regarding the assumptions underlying the outlook; Note: Our achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in our filings with the SEC. The plan does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of our acquisitions, dispositions or financings during 2022. Our plan assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented. 120 BEAUTYHEALTH™#121Bridge to 25-30% adj. EBITDA margin: reaping the benefits of our investments 121 2021 Adj. EBITDA Margin Up to 5% Gains in COGS Value engineering Up to 10% Gains in G&A Fixed cost leverage as infrastructure build completes Gains in S&M Efficiencies as brand awareness increases and mix shifts to consumables 25-30% Expected Margin Note: Adjusted EBITDA is a non-GAAP measure; please refer to the appendix for a discussion of the definition of this measure and important information regarding the assumptions underlying the outlook. 2025E Adj. EBITDA Margin We anticipate continual adjusted EBITDA margin expansion each year, starting with an estimated 18 - 20% margin in 2023 BEAUTYHEALTH™#122Exiting our outsized investment years 122 2021-2022 Growth investments -800 new employees → Recruiter fees Global office / real estate → Experience Centers → Global back-end software infrastructure build - SOX, ERP etc. Third party logistics (3PL) 2023+ Planned growth optimization →Optimized sales & operations planning → Production efficiencies → Fixed cost leverage on higher net sales volume → Improved training & marketing capabilities Productivity gains BEAUTYHEALTH™#123Extracting leverage from gross margin Today Air freight, less-than-load and smaller order sizes → Duplicate costs as localized manufacturing and 3PLs stood up → Globally sourced components, Long Beach assembly Value engineering starting for Syndeo → Multiple third-party manufacturers added globally GAAP gross margin 65.0% 2018 63.9% 2019 56.4% 2020 69.9% 2021 69.1% 1H2022 123 1. Non-GAAP measure; please refer to the appendix for a reconciliation to the most comparable GAAP measure. Adjusted gross margin¹ 70.7% 65.5% ÏÏÏÏ 73.8% 2018 2019 2020 74.0% 2021 72.4% 1H2022 BEAUTYHEALTH™#124Extracting leverage from gross margin Investment 124 3PL in EMEA & APAC ERP to streamline order-to-cash all the way through 3PL integrations Assembly line efficiencies Demand planning and other sales and operations planning tools - CC KAR DOCE FREE FRARIAS XOXGE 2199 EXIT Pramm. Fm. BEAUTYHEALTH™#125Extracting leverage from gross margin Future state 125 Ocean freight, economies of scale Localized manufacturing 3PLs for international operations Streamlined efficiency in sourcing and system assembly In-house consumables production hydrafacial BEAUTYHEALTH™#126Approaching a steady-state G&A Normalized G&A ($mm)¹ GAAP G&A $4 1019 $5 $6 2019 $6 $5 3Q19 $6 $5 4019 $6 $8 1021 $11 $9 Investments in people, experience centers, systems Primarily fixed cost growth 2021 $44 $12 126 1. Non-GAAP measure; please refer to the appendix for a reconciliation to the nearest GAAP measure and discussion of the definition of this measure. 3Q21 $19 $15 $16 4021 $24 Stabilization of G&A spend 1022 $25 Substantial opportunity to generate operating leverage from stabilizing G&A base $16 2022 $28 BEAUTYHEALTH™#127Extracting leverage from G&A Today 127 Nascent commercial presence in international markets with minimal back-end support ERP in rollout phase Four distributors purchased in 3Q21 face life face first LOOZA ESTI BEAUTYHEALTH™#128Extracting leverage from G&A Investment 128 Hiring key talent Public company costs (SOX compliance, D&O, ERP, audits, etc.) Transfer pricing planning and build-out Rent for new small offices and training / experience centers globally hydrafacial ROM& Haz ond LET'S GET PERSONAL BEAUTYHEALTH™#129Extracting leverage from G&A Future state 129 Fully scaled global back office to sustain substantially increased net sales Full commercial presence to develop and penetrate our 16 direct markets globally Established global shared services model ydrangul Lanien (hydrational hydrafacial BEAUTYHEALTH™#130Selling & marketing seasonality in the business Selling & marketing expense as % of net sales 130 41% 1019 38% 2019 37% 3019 34% 4019 36% Reduced investment given COVID impact 1021 39% 2021 Investment years 45% 3021 49% 48% Heavy marketing Syndeo launch to capitalize on market re-openings 4021 1022 43% 2022 BEAUTYHEALTH™#131Extracting leverage from selling & marketing Today 131 8% aided brand awareness Ceiling of international growth potential given limited size of ex-U.S. sales force Outsized investment in physical activation first half of the year Source: Company data. 196 hydrafac hydrafacial BEAUTYHEALTH ® 7 drafacial BEAUTYHEALTH™#132acpl Our biggest selling & marketing events happen in 1H Other notable sales & marketing events hydrafacial IECSC | Las Vegas, NV, USA June 2022 hydrafacial bea 132 cial Beauty Fair | Düsseldorf, Germany May 2022 Infacal 158 (AIS INNOVATION AIST San Diego, CA, USA April 2022 lydnafaqal hydrafacial bydratacial SU X309 then bet 33 svoprey Ra 12X F Werksd hydrafacial DAY TO MINUTES. For the most delicate areas of face AMWC | Monaco April 2022 IMCAS Congress | Paris, France June 2022 hydrafa OF WARTE Whaled TH No Global Sales Meeting (Jan) Estipalooza (May) → GlowVolution (June) BEAUTYHEALTH™#133Extracting leverage from selling & marketing Investment 133 Brand awareness initiatives Hiring key sales, training and marketing (Golden Triangle) talent Global hiring ahead of sales (ie, $20mm more investment compared to 2021) Incentivization of sales force to place systems Training and inside sales support Personalised Skin Health by hydrafacial 1 BEAUTYHEALTH™#134Extracting leverage from selling & marketing Future state 134 Localized and established commercial infrastructure across all direct markets Leverage in commissions as sales mix shifts Reduced need for substantial investments in marketing with broadening brand awareness Optimized sales cycle and lead conversion times FACE LIFE/ LET'S GET PERSONAL WAY JE TO BEAUTYHEALTH™#135Our three-year plan 2x net sales vs. 2022E $600 - $700mm 2025E net sales 20-27% 2022E - 2025E CAGR¹ 135 3x+ Adj. EBITDA vs. 2022E 18 - 20% 25-30% 2023E Adj. EBITDA margin 2025E Adj. EBITDA margin Note: Adjusted EBITDA is a non-GAAP measure. See appendix for a definition and discussion. Our achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in our filings with the SEC. The plan does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of our acquisitions, dispositions or financings during 2022. Our plan assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented; 1. Assuming midpoint of previously stated 2022 $340-350mm net sales guidance. BEAUTYHEALTH™#136Key takeaways 136 2 Successful track record of progress over perfection execution Substantial growth runway ahead 3 Significant profitability potential YOU KNO OU GLO BEAUTYHEALTH™#137BEAUTYHEALTH™ Analyst & Investor Day September 15, 2022#138138 Closing remarks Andrew Stanleick President & Chief Executive Officer BEAUTYHEALTH#139Today's three takeaways q 1 CATEGORY CREATOR with a differentiated product offering, business model and community 139 1800 2 PROFITABLE GROWTH across geographies and categories in a huge and growing TAM Kol 3 INNOVATIVE TECHNOLOGY and a powerful flywheel drives our growth BEAUTYHEALTH™#140140 Questions? BEAUTYHEALTH™#141hydrafacial ransformation Occupied 141 пушагас1ar hy hydra hyd Thank you al BEAUTYHEALTH™#142142 callargal I wdraft cial hydrafacial Ν Υ Appendix BEAUTYHEALTH™#143Disclaimer This Presentation contains certain forward-looking statements. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of The Beauty Health Company (the "Company"), the calculation of certain key financial and operating metrics, capital expenditures, the introduction of new products, expansion into new markets and the ability to execute certain strategic initiatives. Some of the forward-looking statements can be identified by the use of forward-looking words such as "anticipate," "expect," "suggests," "plan," "believe," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "outlook," "forecast" and other similar expressions. These are intended to identify forward-looking statements. All forward- looking statements are based upon management estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company as of the date of this Presentation, and may include, without limitation, changes in general economic conditions as a result of COVID-19, all of which are subject to change. Any such estimates, assumptions, expectations, forecasts, views or opinions set forth in this Presentation constitute the Company's judgments and should be regarded as indicative, preliminary and for illustrative purposes only. The forward-looking statements and projections contained in this Presentation are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause the Company's actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition. Although such forward-looking statements have been made in good faith and are based on assumptions we believe to be reasonable, there is no assurance that the expected results will be achieved. Many factors could adversely affect our business and financial performance. We discussed a number of material risks in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2022 and other filings with the Securities and Exchange Commission. Those risks continue to be relevant to our performance and financial condition. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We expressly disclaim any responsibility to update forward-looking statements, whether as a result of new information, future events or otherwise. The Company does not provide a reconciliation of its expected fiscal 2022, 2023 and 2025 adjusted EBITDA to net income (loss), the most directly comparable forward looking GAAP financial measure, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, which cannot be done without unreasonable efforts, including adjustments that could be made for changes in fair value of warrant liabilities, integration and acquisition-related expenses, amortization expenses, non-cash stock-based compensation, gains/losses on foreign currency, and other charges reflected in our reconciliation of historic numbers, the amount of which, based on historical experience, could be significant. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. The Company's expected fiscal 2022, 2023 and 2025 adjusted EBITDA is merely an outlook and is not a guarantee of future performance. Stockholders should not rely or place an undue reliance on such forward-looking statements. 143 BEAUTYHEALTH™#144Description of Non-GAAP Financial Measures In addition to results determined in accordance with accounting principles generally accepted in the United States of America (GAAP), management utilizes certain non-GAAP financial measures such as adjusted gross margin, adjusted EBITDA, and adjusted EBITDA margin for purposes of evaluating ongoing operations and for internal planning and forecasting purposes. We believe these non-GAAP financial measures, when reviewed collectively with our GAAP financial information, provide useful supplemental information to investors in assessing our operating performance. These non-GAAP financial measures should not be considered as an alternative to GAAP financial information or as an indication of operating performance or any other measure of performance derived in accordance with GAAP, and may not provide information that is directly comparable to that provided by other companies in its industry, as these other companies may calculate non-GAAP financial measures differently, particularly related to non-recurring, unusual items. Management uses adjusted gross margin to measure profitability and the ability to scale and leverage the costs of Delivery Systems and Consumables. The continued growth of Delivery Systems is expected to improve adjusted gross margin, as additional Delivery Systems sold will increase our recurring Consumables net sales, which has higher margins. Management believes adjusted gross profit and adjusted gross margin are useful measures to the Company and its investors to assist in evaluating operating performance because they provide consistency and direct comparability with past financial performance and between fiscal periods, as the metrics eliminate the effects of amortization and depreciation, which are non-cash expenses that may fluctuate for reasons unrelated to overall continuing operating performance. Adjusted gross margin has been and will continue to be impacted by a variety of factors, including the product mix, geographic mix, direct vs. indirect mix, the average selling price on Delivery Systems, and new product launches. Management expects adjusted gross margin to fluctuate over time depending on the factors described above. Management uses normalized G&A to facilitate internal comparisons of historical operating performance on a more consistent basis and uses this measure for business planning purposes. Management also believes this information will be useful for investors to facilitate comparisons of operating performance and better identify trends in the business. Management expects normalized G&A to increase over the long-term, as the Company continues to scale and achieve greater operating leverage. The Company calculates normalized G&A as General & Administrative Expense, adjusted to exclude: depreciation and amortization expense; stock-based compensation expense; one-time or non-recurring items such as transaction costs (including transactions costs with respect to the Business Combination); and restructuring costs (including those associated with COVID-19); and credit card fees. Management uses adjusted EBITDA and adjusted EBITDA margin to facilitate internal comparisons of historical operating performance on a more consistent basis and uses these measures for business planning purposes. Management also believes this information will be useful for investors to facilitate comparisons of operating performance and better identify trends in the business. Management expects adjusted EBITDA margin to increase over the long-term, as the Company continues to scale and achieve greater operating leverage. The Company calculates adjusted EBITDA as net income (loss) adjusted to exclude: change in fair value of public and private placement warrants, change in fair value of earn-out shares liability, other expense, net; interest expense; income tax benefit (expense); depreciation and amortization expense; stock-based compensation expense; foreign currency (gain) loss; management fees incurred from historical private equity owners; one-time or non- recurring items such as transaction costs (including transactions costs with respect to the Business Combination); and restructuring costs (including those associated with COVID-19). 144 BEAUTYHEALTH™#145Reconciliation of net income to adjusted EBITDA Unaudited ($mm) Net revenue Net income (loss) Adjusted to exclude the following: Change in FV of warrant liability Change in FV of earn-out shares liability Amortization expense Stock-based compensation expense Other expense Management fees¹ Transaction related costs² Other non-recurring and one-time fees³ Aggregate adjustment for income taxes Adjusted net income (loss) Depreciation expense Jun-22 $103.5 Interest expense Foreign currency (gain) loss, net Remaining benefit for income taxes Adjusted EBITDA $7.9 (15.2) 3.9 6.4 (1.7) Mar-22 $75.4 2.0 1.9 (3.1) $2.2 1.9 3.2 2.2 3.2 $12.6 12.2% $32.5 72.0 36.5 3.0 3.0 3.5 0.0 4.3 0.0 0.1 0.1 2.6 1.2 30.4 0.7 3.3 0.5 0.1 0.1 (0.8) (2.4) (2.7) (0.8) $1.6 $2.5 $7.8 ($0.1) 2.0 2.4 0.7 0.7 3.5 0.5 2.1 5.7 (0.6) 0.4 (0.0) 0.3 2.0 (0.1) 0.8 0.5 $5.8 $11.4 $7.0 $8.5 10.9% 8.5% 17.1% 14.8% Adjusted EBITDA margin 1. Represents quarterly management fees paid to the former majority shareholder of the Company based on a pre-determined formula. Following the Business Combination, these fees are no longer paid; 2. For the six months ended June 30, 2022, such amounts primarily represent direct costs incurred in relation to potential acquisitions. For the year ended December 31, 2021, such amounts primarily represent direct costs incurred with the Business Combination, including $21.0 million paid to the former owner of HydraFacial, and to prepare HydraFacial to be marketed for sale by HydraFacial's shareholders in previous periods; 3. For the six months ended June 30, 2022, such costs include the re-organization severance, other one-time personnel costs related to executive recruiting, executive severance, a one-time loss on fixed asset write-offs and a CEO sign-on bonus. For the year ended December 31, 2021, such costs primarily represent one-time retention awards related to the distributor acquisitions and executive recruiting and severance fees. 145 BEAUTYHEALTH™ (52.1) 3.7 7.0 0.9 Three months ended Dec-21 $77.9 ($17.3) 1.0 2.0 (3.6) ($8.5) 1.4 3.4 (0.4) 6.2 $2.2 2.9% 6.0 3.9 3.8 0.2 Sep-21 $68.1 ($215.1) I 199.3 10.6 3.5 5.1 (0.0) Jun-21 $66.5 ($139.4) I Mar-21 $47.5 ($3.3) I I#146Reconciliation of net income to adjusted EBITDA Unaudited ($mm) Net revenue Net income (loss) Adjusted to exclude the following: Change in FV of warrant liability Change in FV of earn-out shares liability Depreciation & amortization expense Stock-based compensation expense Other expense (income) Management fees¹ Transaction related costs² Dec-21 $260.1 ($375.1) 277.3 47.1 17.8 12.4 4.5 0.2 34.9 4.0 (14.1) 11.8 0.1 11.8 $32.7 12.6% Year ended Dec-19 $166.6 ($1.6) 13.9 0.1 (0.5) 1.8 1.7 5.7 Dec-18 $112.3 ($0.3) 11.5 0.1 0.0 3.2 0.4 1.0 Other non-recurring and one-time fees³ Aggregate adjustment for income taxes Interest expense 17.1 Foreign currency (gain) loss, net (0.2) Remaining benefit for income taxes (1.3) Adjusted EBITDA $36.7 Adjusted EBITDA margin 22.0% 1. Represents quarterly management fees paid to the former majority shareholder of the Company based on a pre-determined formula. Following the Business Combination, these fees are no longer paid; 2. For the year ended December 31, 2021, such amounts primarily represent direct costs incurred with the Business Combination, including $21.0 million paid to the former owner of HydraFacial; For the years ending December 31, 2019 and December 31, 2018, such amounts represent direct costs incurred to prepare the Company to be marketed for sale by the Company's shareholders in previous periods; 3. For the year ended December 31, 2021, such costs primarily represent one-time retention awards related to the distributor acquisitions and executive recruiting and severance fees. For the years ended December 31, 2019 and December 31, 2018, such costs primarily represent personnel costs associated with restructuring of HydraFacial's salesforce and costs associated with former warehouse and assembly facility during the transition period, to defend certain patents that were being infringed upon and a 2019 relocation to a new assembly and warehouse facility that was completed during December 2019. 146 BEAUTYHEALTH™ 10.0 (0.0) 0.3 $26.2 23.3%#147Reconciliation of gross margin to adjusted gross margin Unaudited ($mm) Net sales Cost of sales Gross profit (GAAP) Gross margin (GAAP) Adjusted to exclude the following: Stock-based compensation expense included in cost of sales Depreciation and amortization expense included in cost of sales Adjusted gross profit Adjusted gross margin 147 Six months ended Jun-22 $179.0 55.4 $123.6 69.1% 0.4 5.6 $129.6 72.4% Dec-21 $260.1 78.3 $181.8 69.9% 0.4 10.3 $192.5 74.0% Year ended Dec-20 Dec-19 Dec-18 $166.6 $119.1 $112.3 51.9 60.1 39.3 $67.2 $106.5 $73.0 56.4% 63.9% 65.0% 10.8 11.3 $78.0 $117.8 65.5% 70.7% 10.0 $82.9 73.8% BEAUTYHEALTH™#148Reconciliation of G&A to normalized G&A Unaudited ($mm) General & administrative expense Adjusted to exclude the following Transaction-related costs and other non-recurring and one-time fees Depreciation & amortization expense Stock-based compensation expense Credit card fees Normalized general & administrative expense 148 Three months ended Jun-22 Mar-22 Dec-21 Sep-21 Jun-21 Mar-21 Dec-19 $28 $25 $24 $19 $44 $11 $6 3 3 4 1 $16 3 1 4 1 $16 6 2 1 0 $15 2 1 4 1 $12 30 - 3-s 1 $9 1 1 O 1 $8 O 1 O $5 Sep-19 $6 0 1 $5 Jun-19 $6 0 1 (0) $6 Mar-19 $5 O 1 O 0 $4 BEAUTYHEALTH™#149BEAUTYHEALTH™ Analyst & Investor Day September 15, 2022